Zai Lab Announces Pricing of Public Offering of American Depositary Shares Read more about Zai Lab Announces Pricing of Public Offering of American Depositary Shares
Zai Lab Announces Proposed Public Offering of American Depositary Shares Read more about Zai Lab Announces Proposed Public Offering of American Depositary Shares
Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018 Read more about Zai Lab Announces Financial Results and Corporate Progress for the Six Months ended June 30, 2018
Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China Read more about Zai Lab Doses First Patient in Phase III Trial of ZL-2306 (niraparib) in Patients with Small-Cell Lung Cancer in China
Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis Read more about Zai Lab Elects to Discontinue Development of ZL-3101 (Fugan) for Atopic Dermatitis
Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC) Read more about Zai Lab Announces Presentations at the 21st Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) and the IASLC 19th World Conference on Lung Cancer (WCLC)
Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients Read more about Zai Lab’s ZL-2306 (niraparib) Completes Pharmacokinetics (PK) Study in Chinese Ovarian Cancer Patients Showing Comparable Profile to non-Chinese Patients
Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors Read more about Zai Lab Appoints Professor Kai-Xian Chen, Ph.D., to its Board of Directors
Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer Read more about Zai Lab Announces Dosing of First Patient in Phase 3 China Registration Trial of ZL-2306 (niraparib) for First-Line Maintenance Therapy in Platinum Responsive Ovarian Cancer
Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer Read more about Zai Lab Expands Commercial Leadership Team, Appoints William Liang as Chief Commercial Officer